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The purpose of this retrospective chart review was to quantify the effectiveness 
of steroid injections have in treating new trigger fingers in patients with a history of 
injection resistant trigger finger.  
METHODS: 
 Forty-three study subjects were defined as those patients who presented with 
trigger finger, underwent at least one steroid injection followed by surgical release of 
the A1 pulley, and subsequently represented with another trigger finger in a distinct 
digit and compared to a group of 40 control subjects presenting with first trigger 
fingers. Demographic data, PMH, and treatments for trigger finger were recorded. 
Subjects were surveyed to assess any residual symptoms and level of satisfaction with 
injection treatment. The control and study groups were then compared by student’s T 
test for any statistically significant differences in measured outcomes. Decision Tree 
Analysis of cost for treatment of repeat trigger finger was employed using Precision 
Tree Software. 
RESULTS: 
The study group had higher proportion of injection resistant trigger finger than 
control group with 49% (21/43) of patients and 38% (35/91) of digits proceeding to 
surgery vs 23% (9/31) of patients and 22% (11/38) of digits in the control group (p 
values 0.01 and 0.05 respectively). There were no significant differences in number of 




first injection or before surgery, patient satisfaction with injection treatment, or patient 
willingness for future injection treatment. 87% (26/30) study group digits had complete 
resolution of symptoms on survey vs 57% (16/39) digits in the control group (p value 
0.011) with the most common side effect being stiffness. 
There were no significant differences in gender, age, and medical comorbidites 
between the two groups including diabetes. The study group had statistically significant 
higher incidence of carpal tunnel syndrome (p value 0.0001), Dupuytren’s disease (p 
value 0.026) and occupational exposure (p value 0.012).The distribution of affected 
fingers differed with trigger thumbs being more prevalent in the control group (p value 
0.0044). Precision Tree Software revealed that injection treatment was a cost efficient 
method of treating trigger digits in patients with previous injection resistant trigger 
finger. 
SUMMARY POINTS: 
Patients returning for with a new trigger finger after having required surgery for 
another finger can still respond to non operative treatment, specifically a steroid 
injection. It is our clinical recommendation that steroid injection treatment should be 
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Trigger finger, or stenosing tenosynovitis, is a condition where the normal smooth 
gliding of the flexor tendons through the fibrous tendon sheath of the digit is altered.  
Inflammation where the flexor tendon enters the sheath leads to either thickening of the 
fibrous pulley and/or inflammation or nodular enlargement of the tendon. This 
enlargement of the tendon results in locking and clicking symptoms of the affected 
finger where the patient is unable to fully extend of flex the finger without the area of 
tendon enlargement becoming trapped within the tendon sheath.  
 
 
Anatomy and Pathobiology of Tenosynovitis 
Normal finger flexion is a finely coordinated movement initiated by the flexor 
digitorum superficialis and profundus that reside in the palm of the hand. The muscle 
belly is connected to the phalanges by a flexor tendon that is guided by a tendon sheath 
and complex pulley system composed of eight focal thickenings of the flexor tendon 
sheaths. These flexor tendon sheath thickenings are referred to as the five annular 
pulleys (A1 thru A5) and the three cruciate pulleys (C1 thru C3) (Figure 1). These 
retinacular structures serve two functions: first they maintain the flexor tendon position 
relative to the bones and second, they provide a fulcrum to generate increased power of 
flexion to prevent bowstringing of the flexor tendon.  
The tendon sheath has a membranous, synovial component. The synovial sheath is a 
double walled hallow tube containing synovial fluid through which the flexor tendon 
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travels that extends proximally to the carpal tunnel in digits I and V, and to the MP joint 
in digits II, III, and IV (1).  
Some controversy exists in the literature regarding the precise histology of the normal 
A1 pulleys and the histology of trigger finger affected pulleys (2) (3) (4) (5). 
Sbernardori and Bandiera compared sections of the central portion of 40 A1 pulleys 
from adult patients with symptoms of trigger finger from sections from 10 healthy 
volunteers were subjected to light and electron microscopy to study the histology and 
ultrastructural make up of the samples (6). They showed differences in the connective 
tissue structure of the normal A1 pulleys vs pathologic ones. Normal pulleys consist of 
two distinct connective tissue layers, an inner layer of organized collagen bundles with 
occasional fibrocytes and scant extracellular matrix, and an outer layer of loosely 
organized collagen (shown in Figure 2). 
They found in the pulleys of triggering digits, there were three distinct histologic layers. 
There was an additional inner layer (labeled c in figure 3) that was not present in the 
normal samples consisting of irregularly organized collagen with more extracellular 
matrix, with round cells organized lacunae and islands of chondroid metaplasia. The 
other two layers were as described for the normal pulleys. The underlying flexor 
tendons exhibit a nodular or fusiform swelling and with granulation tissue—both 
believed to be secondary to stenosis caused by the thickened tendon sheath. 
Chondroid metaplasia, is the formation of cartilage-like cells in tissues where they are 
not normally found. Beyond trigger fingers, this finding has also been described as part 
of a degenerative process that takes place in the rotator cuff supraspinatus tendon (7) 
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and in the ACL (8).  Several cell lines are capable of differentiating into chondroid–like 
structures including fibrocytes (9), tenocytes (10), and synoviocytes (11).  
Several studies have characterized stimuli that are associated with chondroid metaplasia 
in tendons. Giori et al found that the level of compressive and hydrostatic forces on 
tendons correlated with the degree of fibrocartilaginous metaplasia (12). The tissue-
level mechanical stimuli associated with forces where tendons and ligaments had to 
cross bony or fibrous pulleys appeared to regulate cartilaginous and fibrous matrix 
composition of connective tissues.  
The presence of chondroid metaplasia and its association with abnormal mechanical 
stimuli could indicate that the pulley thickening associated with trigger finger is related 
to an increase of pressure in the A1 pulley as a result of abnormal frictional forces 
developed during digital flexion. These forces could precipitate differentiation of 
fibrocytes or other stem cells located in the visceral layer of the pulley towards 
chondrocyte like cells and fibrocartilaginous metaplasia. Based on its anatomic location, 
the A1 pulley, may be particularly stressed during digital motion. 
 
Clinical Presentation and Evaluation 
The classic clinical history of flexor tendon entrapment usually refers to a slow onset of 
pain symptoms that occur more frequently over time. During this “pretrigger” phase, 
pain is worsened by exercise or hand-use intensive labor. Stage II, the “active stage”, 
refers to objective presence of clicking of the symptomatic finger which the patient is 
able to overcome by actively extending the finger. This stage progresses to stage III or 
the “passive” stage during which the patient cannot actively overcome the discrepancy 
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between tendon and flexor sheath diameter. As a result, the patient must manually 
extend the finger by forcing it to straighten with the asymptomatic hand (stage IIIA) or 
the patient is unable flex the finger (stage IIIB). The final stage IV, is the presence of 
rigidity of the finger in a flexion posture (13). These findings are confirmed on physical 
examination (Table 1). 
 
Treatment Options 
Treatments for trigger finger in order of invasiveness include splinting, NSAIDs, 
physical therapy, corticosteroid injections, and surgical release of the tendon sheath. 
There are no level 1 or level 2 studies that assess the effectiveness of exercise, physical 
therapy, splinting, or treatment with non-steroidal anti-inflammatory medication in the 
orthopaedic literature. 
 
Physical Therapy, Exercise, and Splinting 
There are no trials assessing exercise, stretching, mobilization, and hot or cold 
modalities. However there are some studies that assess splinting as a modality for the 
treatment of trigger fingers. The goal of splinting is to alter flexor tendon biomechanics 
to minimize force over the affected joint while maximizing tendon glide (14). At this 
point there is no agreement in the literature as to which joint to include in the splint and 
the degree of joint positioning. There have been no trials comparing different joint 
splint strategies and there are no standardized protocols for splinting. 
Colbourn et al. evaluated the efficacy of custom thermoplastic splinting in 28 patients 
(14). Patients wore a low-profile custom thermoplastic MCP blocking (ring) splint for 
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six weeks and pre and post outcomes measured. After the use of a splint, there were 
statistically significant improvements in the stenosing tenosynovitis grade, numeric pain 
rating scale, the number of triggering events in ten active fists, and in the participant 
perceived improvement in symptoms. Grip strength did not significantly change. 
However, it is impossible to gage the significance of these effects without a control 
group. 
Another prospective study in 21 manual workers assessed splinting of the DIP joint 
(15). Splinting was the primary intervention, and a single corticosteroid injection was 
offered if triggering was stage 4 or greater. After mean follow up of one year, 81% of 
digits (50% of patients) were treated successfully. This study also lacked a control 
group. 
A third study of 50 patients assessed splinting of the MCP joint at 10-15 degrees of 
flexion for an average of 6 weeks (range 3-9 weeks) (16). In this protocol, the DIP and 
PIP joints were free to move. Outcomes of the splinted subjects were compared to 
another 50 patients who received a corticosteroid injection. Treatment was successful in 
66% of splint treated patients as compared to 84% of injection treated patients. 
 
/on-Steroidal Anti-Inflammatory Medication 
Non-steroidal anti-inflammatory medications can be used in the treatment of trigger 
finger for pain control (17). There are no trials in the English literature showing the 
effectiveness of non-steroidal anti-inflammatory medications in the treatment of trigger 






Injections with corticosteroids are the most commonly used treatment for trigger finger 
(18) and were described as early as 1953 (19). The goal is to place the medication 
directly into the flexor tendon sheath, though injection in proximity of the sheath has 
also been shown to be effective (20) (21). Common medication combinations used 
include 0.5 ml of the steroid dexamethasone (4 mg/ml) combined with 0.5 ml of 1% 
plain lidocaine or .5 ml of triamcinolone with 0.5 ml lidocaine mixed in a 3 cc syringe, 
utilizing a 5/8 no 27 needle (22) or 1.0 mL betamethasone, 0.5 mL of 1% plain 
lidocaine and 0.5 mL of 0.5% bupivicane.  
Injection treatment for trigger finger has been shown to be effective in 67% (23) to 93% 
(24) for anywhere from 1-4 injections per finger. A recent double blind randomized 
placebo controlled trial comparing saline placebo injection with 1 mL 
triamcinolonacetonide (TCA) in a total of 50 patient (25 in each group) showed that 
patients in the TCA group had a higher rate of immediate symptom improvement than 
in the control group 16/25 vs 5/25 (p value 0.001) and improvement in triggering 13/24 
vs 5/22 (p value 0.053) (25). While this is the first randomized controlled study 
comparing corticosteroid treatment to placebo, it suffers from low subject enrollment. 
There are two approaches to injection treatment for trigger finger. The conventional 
technique involves direct injections into the flexor tendon over the metacarpal head. 
This technique is associated with significant pain. In 1984, Carlson and Curtis described 
an alternative, midaxial technique that reportedly might minimize patient discomfort 
(26). In this technique the needle is pushed to the bone at the proximal phalange level 
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and then adjusted so that the head of the needle enters the flexor tendon sheath. The 
surgeon will know that they have successfully entered the tendon sheath as the 
medication should be easily injected. Two studies have compared the conventional 
technique (CI) and midaxial technique (MAI). In an abstract presented at the ASSH by 
Bernstein RA, MAI and CI were compared in an RCT in 115 subjects where success 
rates in resolving triggering symptoms were 72% and 73% for CI and MAI respectively 
(p value > 0.05, non-significant) (27). Patients also quantified their pain using a Visual 
Analog Pain scale and there was no statistically significant difference on whether one 
approach was more painful. 
A second study comparing the two techniques quantified pain by Visual Analog Pain 
Scores (VAS) and found scores of 40.19 ± 23.3 and 48.39 ± 26.5 for the MAI and CI 
technique groups, respectively (28). These scores were not statistically significant by 
students T-test. The authors also conducted a Pearson’s chi squared assay. The authors 
categorized patients into groups with pain scores ≥50 and pain scores <50. The chi 
squared test was statistically significant (p value < 0.05), however, it is unclear whether 
these categories are clinically significant, especially given the large spread of data 
(approximated by the standard deviations), non-significance of the student’s T test, and 
arbitrariness of the category distinction given that the VAS score is a continuous 
variable.  
Traditionally, physicians attempt to inject steroid medication within the synovial sheath, 
the goal being to provide the highest concentration of medication possible to the area of 
pathology. Intrasheath injections however do come with additional risk of damage to 
the flexor tendon. The effectiveness of intrasynovial vs extrasynovial injection was first 
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assayed by Taras et al assessed the injection location with radiopaque dye (20). In a 
prospective trial, Taras et al found those subjects who had intrasheath injections had a 
47% resolution of triggering, those who received medication both in the subcutaneous 
tissues and intrasheath (due to leak as tracked with the radiopaque dye) had 50% 
resolution of symptoms, and those who had subcutaneous injection had 70% resolution 
of symptoms. The authors concluded that there was no benefit to intrasheath injection 
compared to subcutaneous injection. 
The relative benefit of intrasheath injections was revisted by Kazuki et al in a 
prospective cohort of 100 patients with triggering symptoms graded into three classes of 
severity (grades I-III in order of increasing severity). There was no control or placebo 
group. They found that pain was relieved in 98% of the cases and triggering relieved in 
74% of cases (21). 
The most common side effects of steroid injection for trigger finger are steroid pain 
flare and skin blanching at the site of injection. The steroid pain flare is an increase in 
pain after the initial injection and is thought to be caused by the crystallization of 
steroid crystals leading to a transient increase in pain that resolves over time (29).  
Other side effects include infection and a transient increase in blood sugar in patients 
with diabetes. The increase in blood sugar in diabetics can be marked, especially the 
first morning after injection where one study showed an average increase in blood sugar 
of 73% above average preinjection levels. The increase in blood sugar can last at least 
five days, with an average increase in blood sugar of 26% above preinjection levels at 
day five (30). A review of the literature reveals case reports of rarer side effects such as 
necrotizing fasciitis (31), multiple pulley rupture (32), delayed flexor digitorum 
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superficialis and profundus tendon rupture (33), and shower emboli with associated 
digital necrosis (34) can be associated with trigger finger steroid injection. 
Rozental et al prospectively followed a cohort of 130 patients with primary presenting 
trigger fingers to quantify prognostic factors associated with symptom recurrence 
including patient demographics, comorbidities, and aspects of their symptom 
presentation (35). They found that insulin dependent diabetes mellitus was a strong 
predictor of symptom recurrence (p <0.01). Independent predictors of surgical release 
included younger age (p < 0.01), multiple symptomatic digits upon initial presentation 
(p < 0.01), and history of other upper extremity tendinopathies (p = 0.02). Interestingly 
duration and severity of symptoms were not for predictors surgical release. This group 
also performed Kaplan-Meir analysis to follow the symptom-free duration following 
injection treatment. Ultimately 56% of the digits followed in their cohort had a 
recurrence of symptoms within one year following injection treatment. 
Injection resistance in patients with diabetes was studied in a prospective, double 
blinded RCT where cohorts of thirty diabetic patients and twenty nine control patients 
were randomized to receive either placebo or corticosteroid injections; success was 
defined as resolution of symptoms such that surgical intervention was not required (36). 
Consistent with the Roznetal study, diabetic patients were found to have a lower success 
rate than non diabetic patients (p value 0.03). Interestingly, within the diabetic group, 
corticosteroids did not decrease the surgery rate significantly over placebo, however, as 
there were only 30 patients in the diabetes group, this study may have been 





Associated Hand Co-morbidities of Trigger Finger 
Both trigger finger and carpal tunnel syndrome are associated with medical conditions 
such as diabetes mellitus, rheumatoid arthritis, and hypothyroidism. Kumar and 
Chakrabarti prospectively followed a group of 551 patients who did not have diabetes, 
RA, or hypothyroidism to determine if there was any independent association of carpal 
tunnel syndrome with trigger finger (37). Kumar and Chakrabarti found that 43% of 
patients with trigger finger also had carpal tunnel syndrome, and 21% of the patients 
with carpal tunnel syndrome also had trigger finger. This study was repeated by 
Rottgers et al who found a similar association between trigger finger and carpal tunnel 
syndrome (38). Rottgers et al also concluded that because of the high rate of 
comorbidity between the two conditions, patients that present with trigger finger should 
also be evaluated for carpal tunnel syndrome and vice versa. 
 
Economic Considerations and Cost Effectiveness 
Two studies have looked the costs associated with trigger finger treatment. In a study 
from the UK, Webb and Stothard (39) conducted a prospective, cost-minimization study 
on patients who presented with common hand conditions such as trigger finger, 
Dupuytren’s disease, and hand ganglions. Each patient who presented to their clinic 
with injection resistant trigger finger was offered percutaneous release. Only those who 
failed two attempts at percutaneous release were then offered open surgical release; 
there were no exclusion criteria. All variable costs associated with the procedures 
including operating room and out-patient room time, basic consumables, nursing and 
anesthesia staffing. Medical personnel staff costs were considered fixed costs and were 
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excluded from analysis. Over the six month time period, 52 patients presented with 
trigger fingers, of which 44/52 (85%) were successfully treated as an outpatient with 
percutaneous procedure, and the remaining 8/52 (15%) were treated surgically. Cost 
savings for trigger finger treated in the outpatient setting vs in the operating room was 
609₤ (15₤ outpatient vs 624₤ surgical) resulting in 609₤ greater net income for the 
provider based on a national tariff income of 1322₤ for trigger finger (Figure 4).  
Cost effectiveness of trigger finger treatment has also been studied in the American 
healthcare system (40). Kerrigan and Stanwix examined five strategies for treating 
trigger fingers including different combinations of injection, surgery, and percutaneous 
release seeking to identify the least costly algorithm. 
Using decision tree analysis (DATA, TreeAge Software Inc), the five strategies were 
used to construct a five branched decision tree. Success in the decision tree was defined 
at no need for additional treatment within 8.0 weeks to 8.5 years (depending on the 
study), whereas failure was defined as necessitating additional intervention or lack of 
relief of symptoms. Success rates for the decision tree were calculated from existing 
literature, using the median success rate from all published trials for a given 
intervention.  The treatment strategies assayed were 1) 1 steroid injection followed by 
surgical release for failures (steroid option 1), 2) 1 steroid injection followed by a 
second injection for failures followed by definitive surgery if needed (steroid option 2), 
3) same as 2) with a third steroid injections before definitive surgery for failures (steroid 
option 3), 4) surgical release, and 5) percutaneous release with definitive surgery for 
failures. The decision tree is shown in Figure 5. 
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The authors found that Steroid option #2 (one steroid injection followed by a second 
injection for failures followed by definitive surgery if needed) was the most cost 
effective option for treatment of trigger finger. On average, surgery cost payers (such as 
private insurance companies and Medicare) between 248% and 340% more than the 
steroid option #2. This option represents the least costly of acceptable treatment 




Statement of Purpose & Hypothesis: 
The goal of this study is to quantify the level of effectiveness steroid injections have in 
treating new trigger fingers in patients with a history of injection resistant trigger 
fingers. Thus the hypothesis is: If steroid injections are as effective in treating trigger 
finger symptoms in patients with previous injection resistant trigger finger as they are in 
primary fingers, then symptom recurrence rates should be equal in a sample of patients 
with primary trigger fingers as in a sample of patients with second trigger fingers who 
needed surgery for previous symptoms. 
 
Clinical Significance: 
There are currently no studies that address the efficacy of steroid injection treatments in 
those patients who have previously failed trigger finger injection treatment. As outlined 
in Kerrigan and Stanwix, there are multiple treatment algorithms for treatment of trigger 
fingers ranging from proceeding directly to surgery to up to three injections before 
considering surgery (40).  There are no best practice guidelines published as of the date 
of this review. Given the potential heterogeneity of treatment algorithms of primary 
trigger fingers, one might assume there is also heterogeneity in the treatment of those 
patients presenting with secondary trigger fingers, especially in those patients who have 
previously had injection resistant fingers. Some orthopaedic surgeons might opt to 
proceed directly to surgical treatment given that the patient has in the past not 
responded to injections, the injections are painful (28), the patient may have a relapse of 
triggering symptoms (35), and surgery is relatively safe and the definitive treatment. 
However, the surgery is not without risks.  
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A recent chart review documented the rates of both major and minor complications in a 
cohort of 43 patients who underwent 78 open releases of A1 pulleys for trigger finger 
(41). The found a major complication rate (i.e. complications that required further 
surgery) of 3% (2/78) and a minor complication rate (i.e. complications that resolved 
with non-operative treatment or did not reduce function) of 31% (24/78). The major 
complications included a synovial fistula that required excision and proximal 
interphalangeal joint arthofibrosis which caused pain. Minor complications included 
decreased range of motion, scar tenderness, pain, and wound erythema. The authors 
noted that the rate of minor complications was surprisingly high. 
The ultimate goal is to provide the patients with effective treatment for their trigger 
finger condition while minimizing risk. Given the potential for both major and minor 
complications during open pulley release for trigger finger, our study hypothesis sought 
to determine whether trial of injection treatment should be attempted in a population of 
patient who had previously failed injection treatment. Steroid injection is a less invasive 
procedure than open release of the A1 pulley and carries a lower rate of complications. 
At the same time, if injections were ineffective in a population of those patients who 
have previously failed injection treatment and required surgery, then patient suffering 






Trigger Finger Sample 
One hundred sixty three patients who presented to the study sponsor’s practice between 
the years of 1999 and 2008 were identified as potential candidates for the chart review 
by CPT code search for code 26055 - Tendon Sheath Incision (eg, for trigger finger)). 
Of these 143 original patients, a subset of 43 patients with a history of at least one 
episode of injection resistant trigger finger treated surgically that subsequently 
developed a second trigger finger treated was identified. Exclusion criteria were 
presence of rheumatologic disease or previous treatment with steroid injection. 
Participants ranged in age from 40 to 84 years at the time of presentation of their index 
case trigger finger (average age at index case presentation 58.8 years). The gender 
distribution between males and females was biased towards females who made up 70% 
of the sample (30 females, 13 males). 
Additional descriptive data collected included past medical history of diabetes, 
hypothyroidism, or OA, non-injection and non-surgical treatment of trigger finger, 
BMI, history of other upper extremity orthopedic conditions, and treatment for upper 




The comparison sample consisted of 56 consecutive patients presenting with primary 
trigger fingers treated with injection between the dates of 3/1/08 and 6/1/08. Exclusion 
criteria were presence of rheumatologic disease, previous treatment with steroid 
injection or surgery for trigger finger. Of the 56 consecutive patients, 40 met eligibility 
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requirements for the study. These participants ranged in age from 44 to 81 years of age 
(average 65 years at time of presentation of index case trigger finger). The gender 
distribution between males and females was biased towards females who made up 65% 
of the sample (26 females, 14 males). Additional descriptive data was collected as 
described for the study group. 
 
Procedure 
The charts of the 83 adults (43 study patients and 40 controls) were reviewed and data 
obtained regarding their past medical history relevant to trigger finger (presence of 
diabetes, insulin treatment for diabetes, hypothyroidism, or gout), demographics (age at 
presentation, BMI, sex, and occupational exposure), as well as the presence of any other 
upper extremity pathology and associated treatment for the upper extremity pathology. 
The subjects were then consented as described in Yale HIC # 0912006039 and surveyed 
by phone using form 1 shown in the Appendix.  
The control and study groups were compared on all metrics including demographic 
information trigger finger characteristics, incidence of treatments including injection 
and surgery, and survey data. A student’s T-test was used to assay the significance of 
differences between the two groups. A P-value of less than or equal to 0.05 was 
considered statistically significant. Success of the corticosteroid injection was defined 





Demographics and Trigger Finger Characteristics 
There were no differences in gender distribution and BMI between the two groups (p 
values of 0.65 and 0.46 respectively). However, there was increased incidence of 
occupational exposure in the study group where the control group subjects had 15% 
(6/40) prevalence of occupation exposure (as reported by the patient as either 
workman’s compensation or hand-intensive occupation or hobby) and while the study 
group had 40% (17/43) prevalence (p value 0.01). There were no differences in the 
prevalence of other medical comorbidities including diabetes (p value 0.95), diabetes 
treated with insulin (p value 0.96), hypothyroidism (p value 0.59), and gout (p value 
0.96). There was no difference between the two groups in the incidence of hand 
osteoarthritis, as diagnosed radiographically (p value 0.36). 
Factors characterizing the trigger finger were tracked. The forty patients in the control 
ultimately presented with forty-nine affected fingers (average 1.23 fingers per patients, 
range 1 to 3 fingers). The forty-three patients in the study group presented with ninety-
one fingers (average 2.12 fingers per patient, range 1 to 6). Right hands were affected 
73% (28/49 fingers) of the time in the control group and 54% (49/91 fingers) of the time 
in the study group (p value 0.11). Dominant hands were affected nearly twice as often 
in the control group than the study group 73% vs 42% though with the numbers 
available this was not statistically significant (p value 0.08).  
The distribution of fingers affected also differed between the control group and the 
study group. Trigger thumbs were more prevalent in the control group with 41% (20/49) 
of digits affected as opposed to 19% (14/91) in the study group (p value 0.0044). There 
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was a statistically significant higher prevalence of index fingers in the study group as 
well with 15% (14/91) fingers affected as opposed to 4% (2/49) in the control group (p 
value 0.045). Overall, the distribution of trigger digits was more even in the study group 
as opposed to the control group where the majority of digits affected were thumbs, 




As described previously, several hand conditions have been associated with trigger 
finger. Seven of the most common upper extremity conditions were tracked for 
comparison. Statistically significant differences between the study and control groups 
were found in the prevalence of carpal tunnel syndrome and Dupuytren’s disease (p 
values 0.0001 and 0.026 respectively). Prevalence levels of other hand conditions such 
as the presence of cysts, Dequervain’s tenosynovitis, RSI, shoulder impingement, and 
epicondylitis  were not statistically different (p values ranging from 0.59 to 1.00). 
Levels of treatment for other hand morbidities ranged from non-operative interventions 
such as splints, physical therapy, injections, and NSAIDs, as well as surgical procedures 
were not statistically different between the control and study groups (p values ranging 




Patients were surveyed by telephone to 1) determine if patients had any treatments for 
trigger finger besides those documented in the patient’s charts and 2) to quantify the 
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residual symptoms and relative satisfaction the patient had with injection treatment for 
trigger finger. Eighty percent (32/40) of control group patients were available for 
followup vs only 56% (24/43) of study group patients (p value 0.019). This was likely 
due to the fact that many study patients were several years out from their last visit for 
trigger finger and their contact information was not updated. No patients in either the 
control group or the study group had either injection treatment or surgery for trigger 
finger at any facility outside of RAB’s practice. 
Patients were also surveyed regarding any residual symptoms after either injection 
treatment or surgery. Final followup was defined as the time elapsed from the last 
injection treatment to the date of survey and was 44.75 months (range 3.53-112.73) for 
the study group and final follow-up 16.3 months (range 5.0-21.3) for the control group. 
The most common symptom after injection treatment was stiffness in 32% (9/28) 
control subjects and 0% (0/24) study subjects (p value 0.011). Pain was the second most 
common symptom in 11% (3/28) control group subjects and 10% (3/30) in the study 
group. No patients in either group who had injection treatment were experiencing any 
clicking or locking at followup. 91% (21/23) of patients in the control group were 
satisfied with injection treatment for trigger finger vs 83% (10/11) in the study group (p 
value 0.5). Ninety one percent (21/23) of patients in the control group would be willing 
to undergo injection treatment for trigger finger again vs 83% (10/11) in the study group 




Injection Efficacy and Surgery Rates 
We assayed whether longer duration of trigger finger symptoms before injection 
treatment with increased nonoperative treatment failure rates. Tables 6a, 6b, and 6c 
compare the duration of symptoms before first injection and duration of symptoms 
before surgery to see if there was any difference. Table 6a compares patients in the 
control group who either required to surgery or those who did not. The average time 
between onset of triggering symptoms before first injection was 15.45 weeks in those 
who had surgery for trigger finger vs. 16.08 weeks for those control group patients who 
did not need surgery for their symptoms (p value 0.94). Time till surgery was 58.06 
weeks for the control + surgery group. 
Table 6b illustrates the same analysis for the study group. In patients in the study group 
who went onto have surgery for their triggering symptoms there was 15.20 week 
duration before first injection vs. 12.93 weeks for those study group patient who did not 
need surgery (p value 0.56). Time from onset of symptoms to surgery was 101.74 
weeks for the study group. 
Table 6c compares the control group with the study group. Among those patients who 
had surgery, the control group averaged 15.45 weeks and the study group averaged 
15.20 weeks before first injection (p value 0.97). The control group averaged 58.06 
weeks of symptoms before surgery vs. 101.74 weeks for the study group (p value 
0.073). Among those who did not need surgery for their triggering symptoms, the study 
group had on average 16.08 weeks symptoms before first injection and the study group 
averaged 12.93 weeks (p value 0.55).  
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The absolute prevalence of surgical treatment in the control and study groups was 
compared. There were 23% (9/40) control group patients who needed surgery for their 
symptoms vs. 49% (21/43) of patients in the study group (p value 0.01). Among digits, 
22% (11/49) of digits in the control group needed surgery vs. 38% (35/91) in the study 
group (p value 0.05).  
 
Effect of Diabetes 
In Rozental et al, diabetes was found to be independently correlated with inferior 
outcomes of corticosteroid injection treatment (35). Table 9 shows the surgery rates for 
the diabetic and non-diabetic patients in both the control and study groups. In our 
sample groups, 25% (10/40) control group and 26% (11/43) study group had diabetes 
with 2.5% (1/40) insulin dependent diabetics in the control group and 2.3% (1/43) 
insulin dependent diabetics in the study group. There were no significant differences in 
the rates of surgery when comparing diabetic to non-diabetic patients, and when 
comparing control and study groups (p values ranging 0.30-0.94). 
 
Multiple Presenting Fingers vs. Single Presenting Fingers 
In Rozental et al, patients who presented with multiple trigger fingers had higher rates 
of corticosteroid injection treatment failure than those patients who presented with a 
single symptomatic finger (35). Table 10 shows the surgery rates for those who 
presented with multiple and single digits in both the control and study groups. Contrary 
to Rozental’s study, there were no significant differences in the rates of surgery when 
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comparing multiple finger presenting and single finger presenting patients, and when 
comparing control and study groups (p values ranging 0.15-0.96). 
 
Decision Tree Analysis 
A decision tree analysis using Precision Tree Software© (Palisade Decision Tools) was 
performed using reimbursement values from Medicare obtained from Kerrigan et al of 
$171 for corticosteroid injection and $1227 for open release of flexor tendon for trigger 
finger (40). These direct costs included professional fees (those fees paid to the 
orthopaedic surgeon and anesthesiologist) and technical fees (incidental hospital costs, 
medications, supplies, nursing costs and equipment). Indirect costs were not considered 
(opportunity cost of time, QALY, etc). There were four treatment arms in our analysis 
for patients with previous injection resistant trigger finger requiring surgery 
representing with a new and distinct trigger finger: 1) Default directly to surgery, 2) 
One injection, if failure then surgery, 3) Two injections, if failure then surgery, 4) Three 
injections, if failure then surgery. Probabilities for the success of each arm were taken 
from the chart review data in this study. The decision tree was constructed and we 
found that with a success rate of 36.67% in our data set, three corticosteroid injections 
followed by surgery had the least economic impact at an average cost of $678.43. Three 
branch decision analysis shown in Figure 9 analyzes the economic impact of 1) Default 
directly to surgery, 2) One injection, if failure then surgery, 3) Two injections, if failure 
then surgery. The total value of the decision was $791.12 with the injection strategy of 





Stenosing tenosynovitis is a disease where there is gradual growth of a fibrous tissue 
over the flexor tendon of a finger or thumb that eventually leads to a relative narrowing 
of the flexor tendon sheath. This leads to friction between the thickened flexor tendon 
nodule and the connective tissue pulleys leading to pain, restricted movement, and the 
characteristic triggering or “popping” symptoms associated with trigger finger. A 
commonly accepted treatment protocol for primary presenting trigger finger is a trial of 
up to two corticosteroid injections into the tendon sheath followed by surgical release of 
the restrictive pulley if non-operative treatment is not successful. At this point, there are 
no studies addressing treatment protocols for those patients with a history of injection 
resistant trigger finger who present with new, distinct trigger. The hypothesis for this 
study originated when patients asked the study’s sponsor, “because surgery was needed 
for another finger, will cortisone work for the new finger?” 
The primary goal of the study was to determine the relative success rate of 
corticosteroid injections in our study population as compared to a control population of 
patient presenting with primary trigger fingers. As shown in Table 7, there was a 
statistically significant difference in the surgery rates where 49% (21/43) of study 
patients, 38% (35/91) of study digits had surgery (and thus failed non-operative, steroid 
injection therapy). This is compared with control group surgery rates of 23% (9/40) 
patients and 22% (11/49) digits (p values of 0.01 and 0.05 respectively). Patients in the 
study group had higher rates of surgery than those patients in the control group who 
were presenting with their first or primary finger. This result is significant for 
counseling patients who return with multiple trigger fingers in distinct digits after 
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having surgery for previous trigger finger as in this cohort, 51% of patients avoided 
surgery by using the less invasive injection treatment. 
Long term follow up by telephone survey of those patients who underwent successful 
injection treatment found that the vast majority of both control group and study group 
patients were satisfied with injection treatment and would have the treatment again if 
needed. No patients underwent trigger finger treatment outside the study practice. The 
average follow up for the control group was significantly less than for the study group 
(average 16.03 months, range 5.0-21.3 for the control group vs 44.75 months, range 
3.53-112.73 for the study group). The reason for this discrepancy was because the study 
group was gleamed from the entire duration of the sponsor’s practice while the control 
group was obtained from a group of 50 consecutive patients who presented during a 
randomly chosen period of 3/2008-6/2008. 
There was a statistically significant higher incidence of stiffness as a residual symptom 
after corticosteroid injection in the control group than in the study group in the 
telephone survey. Patients with 9/39 digits surveyed in the control group reported 
symptoms of stiffness vs. patients with 0/55 digits surveyed in the study group (p value 
0.0005). This may be because all patients in the study group had surgery and injection 
treatments as well as a higher prevalence of hand pathology in general and thus have a 
different baseline for stiffness than the control group. Study group patients may be less 
likely to report mild symptoms of stiffness due to their higher baseline of pathology. 
A secondary goal of the study was to determine characteristics of the study group that 
were distinct from a group of patients presenting with first trigger fingers (the control 
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group). Demographics analysis revealed that age, gender ratio, BMI, past medical 
history (including diabetes, hypothyroidism, and gout) were not significantly different 
between the control and study groups. Occupational exposure including hobbies was 
significantly higher in the study group than the control group (40% study group vs 15% 
control group, p value 0.0012). In addition to higher rates of occupational exposure, 
there were higher rates of carpal tunnel syndrome and dupuytren’s contracture (p values 
0.0001 and 0.026 respectively). The study group had a 44% incidence of carpal tunnel 
syndrome which when compared to the general population incidence of carpal tunnel 
syndrome is 0.1-0.3% per year with prevalence of approximately 0.5% (42). The high 
rates of carpal tunnel syndrome in our study group, consistent with previous studies (37) 
(38), underscores the need for patients with trigger finger to be concomitantly evaluated 
for carpal tunnel syndrome. The higher incidence of occupational exposure may the 
study group had a higher incidence of more diffuse hand pathology than the control 
group.  
Interestingly, the distribution of triggering digits differed in the control and study 
groups. The dominant hand was more often affected in the control group (73% of the 
digits affected were from the dominant hand) while there was a more even distribution 
of triggering digits in the study group (only 42% of the digits affected were from the 
dominant hand); however this trend only approached significance with a p value of 
0.083). The thumb was most often affected in the control group (41% of the time), 
while there was a more even distribution of affected digits in the study group. Together 
with the higher incidence of diffuse hand pathology, the distribution of affected digits 
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may indicate that there is an underlying predisposition to hand pathology rather than 
distinct overuse of a particular digit such as the thumb. 
Rozental et al showed that insulin dependent diabetes mellitus and presentation with 
multiple fingers were independent predictors of non-operative management failure (35). 
On the contrary, our sample did not show any association with of comorbidity with 
diabetes or multiple fingers at first presentation with surgery rates. This could be due to 
sampling error as our samples were smaller than the cohort in the Rozental study. 
Consistent with the Rozental study, our samples did not show an association of duration 
of symptoms to first corticosteroid injection with surgical intervention. 
The economic viability of treatment protocol options was explored in the framework of 
Kerrigan et al’s study (40). Two decision tree analyses were performed, one including 
all data including those patients who against medical advice received opted to receive 
three corticosteroid injections in a single finger, and a second decision tree which only 
analyzed those patients that received either one or two injections, or surgery. Both 
decision trees showed that it was cost effective to proceed with three or two 
(respectively) injections rather than proceeding directly to surgery in those patients who 
had previously failed non-operative treatment for trigger finger. Sensitivity analysis 
revealed that the reimbursement rate of trigger finger surgery would have to fall below 
$678.43 in the case of three injections or below $791.12 in the case of two injections in 
order to favor surgery earlier in the treatment protocol.  
There only a handful of studies as reported in Kerrigan et al have ever reported success 
rates of three corticosteroid injections for trigger finger, and there are no reports of the 
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success rates in patients with previous injection resistant trigger finger. Based on the 
limited data associated with three rounds of steroid injection for trigger finger, it is 
safest to follow the conventional trigger finger treatment protocol of a trial of up to two 
steroid injections followed by surgery if non-operative treatment fails for patients with a 
history of injection resistant trigger finger who present with new and distinct trigger 
digit(s). 
 
Study Shortcomings and Future Directions: 
The basic design of this study was a retrospective chart review that is considered a level 
3 study. While the results of this study provide the first evidence to support the use of 
corticosteroid injections in patients who have had previous injection resistant trigger 
finger, it cannot be the basis on which clinical recommendations are made. Clinical 
recommendations are made based prospective, level 1 and level 2 clinical trials and 
cohort studies. 
One reason a retrospective chart review was chosen as an initial study was as an initial 
assay of the efficacy of steroid injections in patients with previous injection resistant 
trigger finger was because of the relative rarity of the condition and clinical scenario. 
As outlined in the results of this study, of the many patients who presented to RAB’s 
practice with primary trigger fingers over 10 years, only 143 patients needed open 
surgical intervention for their triggering symptoms after steroid injection treatment. Of 
those 143 patients who had surgery, only 43 patients returned after their surgeries with 
another distinct trigger digit. A prospective trial recruiting patients presenting with first 
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primary trigger digits would likely need to enroll 1000 patients in order to get a 
sufficient number of patient who proceed to surgery for their triggering symptoms, and 
then enough patients to return from surgery with another distinct finger to conduct a 
sufficiently powered analysis of the efficacy of steroid injections. A prospective trial of 
corticosteroid injections conducted in this fashion, or another similar prospective study 
would be necessary to establish firm clinical guidelines or recommendation for the use 
of steroid injections in these patients. 
One potential shortcoming of the chart review conducted in this thesis was the lack of 
use of a standardized outcome measure to provide a validated meaure of the patient’s 
subjective impression of the level of function and disability associated with their trigger 
digit(s) after injection treatment. The use of the DASH inventory was considered during 
the initial study design but was included not as the DASH has questions pertaining to 
the entire upper extremity and may not be sensitive enough to show subtle changes in 
the function of a single finger. The minimum difference in DASH inventory score 
necessary to show a clinically significant difference in outcome is 10 points and there 
may not be enough questions that pertain to finger specific function to be detected by 
the DASH. Another possible inventory that could be considered would be the Michigan 
Hand Outcomes Questionnaire.  Given the low rates of finger complications and 
disability associated with injection, the phone survey was optimized to minimize 
confusion and focus on general satisfaction with treatment, our definition of “success” 
of injection treatment (+/- triggering), and rate of surgery. Should there be a prospective 
study looking at success rates of injections in this population with in-office visits, then 
an outcomes assessment should be used. 
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Finally, the cost analysis done in this study took into only took into account the direct 
costs associated with the treatment of trigger finger. In the pay-for-service  model of 
healthcare that is present in the US, the direct costs to the third party payers such as 
insurance companies associated with trigger finger treatment can be approximated by 
the reimbursement rate for the CPT codes for injection into tendon or sheath and the 
code for open release of pulley for trigger finger. Ideally, a thorough costs analysis 
study would include other, indirect costs associated with treatment such as post 
operative care (revision surgery, rehabilitation, palliative and/or pharmacologic pain 
relief), the opportunity costs of the patient’s time that might be spent more productively 
at work and the impact the condition and/or the treatment have on the patient’s life. The 
latter, the impact the condition and/or treatment have on the patient’s life can be 
approximated by the Quality Adjusted Life Year (QALY) which is a measure of disease 
burden and can be used as an outcomes measure. 
Currently there are no models for QALY or accepted rates of complication associated 
with corticosteroid injections for trigger finger and only one retrospective chart review 
characterizing the complication rates of open surgical release for trigger finger (41). 
Given the lack of evidence characterizing complication rates and the subjective nature 
of determining QALYs for conditions such as trigger finger, the decision tree analysis 
in this study was limited to direct costs, approximated by the Medicare reimbursement 






There are no published studies examining the responsiveness of trigger finger in 
patients with previous injection-resistant tenosynovitis in the English literature. Our 
study demonstrates that corticosteroid injections are effective in relieving the symptoms 
of triggering in 51% of patients and 62% of digits in our sample with previous injection 
resistant trigger finger presenting with symptoms in a distinct finger. Patients with 
injection resitant trigger finger have a higher rate of comorbidity with carpal tunnel 
syndrome and Dupuytren’s contracture. Additionally, it is cost effective to follow a 
treatment strategy of a trial of two corticosteroid injections followed by surgery as 
opposed to proceeding directly to surgery. It is our clinical recommendation that a trial 
of up to two corticosteroid injections should considered for patients with a history of 
injection resistant trigger finger presenting with new and distict idiopathic tenosynovitis 
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Figure 1: Anatomy of flexor tendon showing the intricate pulley system that guides finger 
flexion. The pulley most often affected in trigger finger and subsequently released during open 
release for trigger figner is the A1 pulley.  
Medscape. Flexor Tendon Anatomy: eMedicine Clinical Procedures. [Online] January 4, 2010. 

























Figure 2: Normal vs. pathological A1 pulley showing two normal layers of connective tissue in 
the top panel and three layers in the pathologic pulley. The inner layer, marked c, is postulated 
to be pathologic tissue. 
Histopathology of the A1 pulley in adult trigger fingers. Sbernardori MC, Bandiera P. 2007, J 






















Figure 3: Chondroid Metaplasia in the pathologic A1 pulley (shown by arrows)  
 
Histopathology of the A1 pulley in adult trigger fingers. Sbernardori MC, Bandiera P. 2007, J 










Figure 4: Costs associated with outpatient and surgical treatment in the UK. These are direct 
costs including both professional and technical fees including supplies.  
Cost minimisation using clinic-based treatment for common hand conditions--a prospective 


































































































































































































































































































































































































































































































































































Figure 7:  Chart of Outcome Probabilities 
 
 
Figure 7: The bar chart shows the probability and value of each outcome in the decision tree 
shown in Figure 6b.  
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Figure 8: The sensitivity analysis varies the cost of surgery against the cost of injection. The point 






















































































































































































































































































Table 1: Classification of Trigger Fingers as in Wolfe SW. Tenosynovitis. In: Green DP, 
Hotchkiss R/, Pederson WC, eds. Green's operative hand surgery, 4th ed. New York:  : 
Churchill Livingstone, , 1999:2022–2044. (13). 
TABLE 1. CLASSIFICATIO/ OF TRIGGER FI/GERS 
Grade  Characteristics 
I (pretrigger) 
 
Pain; positive sign of trigger finger not 
evaluated during the objective medical 
examination; increased sensibility toward 
pain in correspondence with the first 
annular pulley. 
II (active)  Objective presence of trigger finger; the 
patient is able to extend the finger actively. 
III A (passive) Objective presence of trigger finger. 
Extension is only possible passively with 
the help of an applied external force 
III B Objective presence of trigger finger. 
The patient is unable to actively flex the 
finger. 
IV (rigidity) in a flexion posture. Objective presence of trigger finger; the 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 6a: Duration of Symptoms before first injection and before surgery for the control group 
CONTROL       
All Patients Weeks       
Time from Onset of Symptoms 
to First Injection 16.06 
Time from Onset of Symptoms 
to Surgery N/A       
  
Patients that had Surgery Weeks 
Patients that did not have 
Surgery Weeks P value 
Time from Onset of Symptoms 
to First Injection 15.45 
Time from Onset of 
Symptoms to First Injection 16.08 0.94 
Time from Onset of Symptoms 
to Surgery 58.06 
Time from Onset of 





Table 6b: Duration of Symptoms before first injection and before surgery for the study group 
STUDY GROUP         
All Patients Weeks       
Time from Onset of Symptoms 
to First Injection 14.11 
Time from Onset of Symptoms 
to Surgery N/A       
    
Patients that had Surgery Weeks 
Patients that did not have 
Surgery Weeks P value 
Time from Onset of Symptoms 
to First Injection 15.20 
Time from Onset of 
Symptoms to First Injection 12.93 0.56 
Time from Onset of Symptoms 
to Surgery 101.74 
Time from Onset of 





Table 6c: Duration of Symptoms before first injection and before surgery of study vs control 
group 
CONTROL   STUDY GROUP   P Value 
All Patients Weeks All Patients Weeks 
Time from Onset of Symptoms 
to First Injection 15.91 
Time from Onset of 
Symptoms to First Injection 14.11 0.64 
Time from Onset of Symptoms 
to Surgery N/A 
Time from Onset of 
Symptoms to Surgery N/A 
        
Patients that had Surgery Weeks Patients that had Surgery Weeks 
Time from Onset of Symptoms 
to First Injection 15.45 
Time from Onset of 
Symptoms to First Injection 15.2 0.97 
Time from Onset of Symptoms 
to Surgery 58.06 
Time from Onset of 
Symptoms to Surgery 101.74 0.073 
Patients that did not have 
Surgery Weeks 
Patients that did not have 
Surgery Weeks 
Time from Onset of Symptoms 
to First Injection 16.08 
Time from Onset of 
Symptoms to First Injection 12.93 0.55 
Time from Onset of Symptoms 
to Surgery N/A 
Time from Onset of 





Table 7: Surgery prevalence among the control and study groups 
  Control Percentage Study Percentage P value 
Total Patients 40   43     
Number of Patients + Surgery 9 23% 21 49% 0.01 
Number of Patients - Surgery 31 78% 22 51% - 
Total Digits 49 91   
Number of Digits + Surgery 11 22% 35 38% 0.05 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 Table 9: Diabetes 
  Surgery 
No 
Surgery Percentage P value 
Control Diabetes + 1 7 13% 0.3 
Control Diabetes -  8 24 25%   
Study Group Diabetes + 5 6 54% 0.94 
Study Group Diabetes -  16 17 48%   
P value 0.44 0.63     
 
Table 10: Multiple Presenting Fingers vs Single Presenting Fingers: 
  Surgery 
No 
Surgery Percentage P value 
Cont Multiple Finger Presentation  0 3 0% 0.34 
Cont Single Finger Presentation 9 28 24%   
Study Multiple Finger Presentation  2 2 50% 0.96 
Study Single Finger Presentation 19 20 49%   





Form 1: Consent Script and Survey Data Collection Sheet 
 Hello this is ________________. I am contacting you because you are a potential volunteer in a 
study being conducted by Dr. Bernstein’s office at The Orthopaedics Group, LLC. We are 
conducting a survey on your experience with injection treatment for trigger finger studying how 
effective injections were in treating your symptoms. This study takes about 10 minutes and you 
are under no obligation to participate. If you have any questions at anytime during this survey, do 
not hesitate to ask. Your participation in this survey will in no way affect your relationship with 
The Orthopaedics Group, LLC. The information obtained in this survey such as your name and 
symptoms and treatment for trigger finger will be used in conjunction with your information from 
you medical records like your past medical history relevant to trigger finger and symptoms and 
treatment of trigger finger and later de-indentified. This information will be protected by securely 
storing the information in password protected documents on password protected computers, with 
monthly security reviews. Do you consent to participate in this survey and for the use of your 
protected health information as described for this study? 
 
Subject Name:____________________________Date of Survey:_________________________ 
Consent Given:___________________________Date of Consent:________________________ 
Consent Obtained by:______________________ 
Hand Affected:  Right  Left  Finger Affected: T     I     L     R     S 
Are you having pain in the previously injected finger?  Yes  No 
If yes then rate pain:     0     1     2     3     4     5     6     7     8     9     10  (10=max, intolerable) 
Are you experiencing any stiffness in the previously injected finger?    Significant   Mild     None 
Are you experiencing any clicking/locking in the finger?                      None     Rare       Constant 
Have you received treatment anywhere else for the previously injected finger?      Yes       No 
If yes  What was done?  Surgery   Therapy  Injection Other______________________________ 
Did you have surgery on the trigger finger? 
If no to the surgery question 
Were you satisfied with the injection treatment for the trigger finger?    Yes No 
Would you have the injection treatment again if needed?  Yes  No 
